Login to Your Account



Pharma: Clinic Roundup


Friday, October 11, 2013
• Sihuan Pharmaceutical Holdings Group Ltd., of Hong Kong, said the China Food and Drug Administration accepted its application for clinical trial approval of pirotinib. In preclinical studies, the second-generation inhibitor, aimed at the treatment of lung and breast cancer, demonstrated beneficial profiles in pharmacology, pharmacokinetics and toxicology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription